Histone deacetylase inhibitors as potential therapeutic agents for the treatment of malignant mesothelioma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 3, 2013, Pages 476-482

  Katafygiotis, Patroklos ^a   Giaginis, Constantinos ^b   Patsouris, Efstratios ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

Author keywords

Apoptosis; Cancer; Cell proliferation; Clinical trials; Histone deacetylase inhibitors; Mesothelioma

Indexed keywords

BELINOSTAT; BUTYRIC ACID; CISPLATIN; DEPSIPEPTIDE; ETOPOSIDE; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PEMETREXED; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P21; SUBEROHYDROXAMIC ACID; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

APOPTOSIS; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DROWSINESS; FATIGUE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; TREMOR; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MESOTHELIOMA; MICE; NEOPLASM PROTEINS; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84876709414     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313030010     Document Type: Review

References (52)

1. Wagner, J.C.; Sleggs, C.A.; Marchand, P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med., 1960, 17, 260-271.
2. Bianchi, C.; Giarelli, L.; Grandi, G.; Brollo, A.; Ramani, L.; Zuch, C. Latency periods in asbestos-related mesotheliomaof the pleura. Eur. J. Cancer Prev., 1997, 6, 162-166.
3. De Klerk, N.H.; Musk, A.W.; Williams, V.; Filion, P.R.; Whitaker, D.; Shilkin, K.B. Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom GorgeW, Australia. Am. J. Ind. Med., 1996, 30, 579-587.
4. Price, B. Analysis of current trends in United States mesothelioma incidence. Am. J. Epidemiol., 1997, 145, 211-218.
5. rd ed.; Springer-Verlag: Berlin, 1999.
6. Reed, J.C. Dysregulation of apoptosis in cancer. Cancer J Sci Am. 1998;4(Suppl 1):S8-14.
7. Green, D.R.; Reed, J.C. Mitochondria and apoptosis. Science, 1998, 281, 1309-1312.
8. Jin, J.; Cai, Y.; Li, B.; Conaway, R.C.; Workman, J.L.; Conaway, J.W.; Kusch, T. In and out: histone variant exchange in Chromatin. Trends Biochem. Sci., 2005, 30, 680-687.
9. Lorch, Y.; Maier-Davis, B.; Kornberg, R.D. Chromatin remodeling by nucleosome disassembly in vitro. Prac. Natl. Acad. Sci. USA, 2006, 103, 3090-3093.
10. Saha, A.; Wittmeye, Jr.; Cairns, B.R. Chromatin remodelling: the industrial revolution of DNA around histones. Nat. Rev. Mol. Cell. Biol., 2006, 7, 437-446.
11. Woodcock, C.L. Chromatin architecture. Curr. Opin. Struct. Biol., 2006, 16, 213-224.
12. Shahbazian, M.D.; Grunstein, M. Functions of site-specific histone Acetylation and deacetylation. Annu. Rev. Biochem., 2007, 76, 75-100.
13. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human Disease and prospects for epigenetic therapy. Nature, 2004, 429, 457-463.
14. Li, H.; Zhu, H.; Xu, C.J.; Yuan, J. Cleavage of BID by caspase8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 1998, 94, 491-501.
15. Luo, X.; Budihardjo, I.; Zou, H.; Slaughter, C.; Wang, X. Bid, a Bcl2 interactingpr otein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 1998, 94, 481-490.
16. Wang, X. The expanding role of mitochondria in apoptosis. Genes Dev., 2001, 15, 2922-2933.
17. Soini, Y.V.; Kinnula, W.R.; Kaarteenhaho, E.; Kurttil, K.; Linnainmaa, P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X and bax in malignant mesothelioma. Clin. Cancer Res., 1999, 5, 3508-3515.
18. Cao, X.X.; Mohuiddin, I.; Ece, F.; McConkey, D.J.; Smythe, W.R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am. J. Respir. Cell. Mol. Biol., 2001, 25, 562-568.
19. Neuzil, J.; Swettenham, E.; Gellert, N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem. Biophys. Res. Commun., 2004, 314, 186-191.
20. Pass, H.I.; Stevens, E.J.; Oie, H.; Tsokos, M.G.; Abati, A.D.; Fetsch, P.A.; Mew, D.J.; Pogribniak, H.W.; Matthews, W.J. Characteristics of nine newly derived mesothelioma cell lines. Ann. Thorac. Surg., 1995, 59, 835-844.
21. Schrump, D.S.; Waheed, I. Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas. Semin. Cancer Biol., 2001, 11, 73-80.
22. Yu, X.; Guo, Z.S.; Marcu, M.G.; Neckers, L.; Nguyen, D.M.; Chen, G.A.; Schrump, D.S. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl. Cancer Inst. (Bethesda), 2002, 94, 504-513.
23. Dao, M.; Nguyen, W.D.; Schrump, G., Aaron Chen, et al. Abrogation of p21 Expession by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells. Clin. Cancer Res., 2004, 10, 1813-1825.
24. Ueda H.; Manda, T.; Mukumoto, S.; Nishigaki, F.; Kawamura, I.; Simomura, K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo), 1994, 47, 315-323.
25. Sandor, V.; Senderowicz, A.; Mertins, S.; Sackett D.; Sausville, E.; Blagosklonny, M.V.; Bates, S. E. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer, 2000, 83, 817-825.
26. Blagosklonny, M.V.; Robey, R.; Sackett, D.L.; Du, L.; Traganos, F.; Darzynkiewicz, Z.; Fojo, T.; Bates, S.E. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol. Cancer Ther., 2002, 1, 937-941.
27. Symanowski, J.; Vogelzang, N.; Zawel, L.; Atadja, P.; Pass, H.; Sharma, S. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J. Thorac. Oncol., 2009, 4, 149-160.
28. Crisanti, M.C.; Wallace, A.F.; Kapoor, V.; Vandermeers, F.; Dowling, M.L.; Pereira, L.P.; Coleman, K.; Campling, B.G.; Fridlender, Z.G.; Kao, G.D.; Albelda, S.M. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol. Cancer Ther., 2009, 8, 2221-2231.
29. Vandermeers, F.; Hubert, P.; Delvenne, P.; Mascaux, C.; Grigoriu, B.; Burny, A.; Scherpereel, A.; Willems, L. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res., 2009, 15, 2818-2828.
30. Göttlicher, M.; Minucci, S.; Zhu, P.; Krämer, O.H.; Schimpf, A.; Giavara, S.; Sleeman, J.P.; Lo Coco, F.; Nervi, C.; Pelicci, P.G.; Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducingd ifferentiation of transformed cells. EMBO J., 2001, 20, 6969-6978.
31. Phiel, C.J.; Zhang, F.; Huang, E.Y.; Guenther, M.G.; Lazar, M.A.; Klein, P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant,mood stabilizer, and teratogen. J. Biol. Chem., 2001, 276, 36734-36741.
32. Ziauddin, M.F.; Yeow, W.S.; Maxhimer, J.B.; Baras, A.; Chua, A.; Reddy, R.M.; Tsai, W.; Cole, G.W. Jr.; Schrump, D.S.; Nguyen, D.M. Valproic acid, an antiepileptic drugw ith histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/ TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia, 2006, 8, 446-457.
33. Richon, V.M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R.A.; Marks, P.A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 1998, 95, 3003-3007.
34. Hurwitz, J.L.; Stasik, I.; Kerr, E.M.; Holohan, C.; Redmond, K.M.; McLaughlin, K.M.; Busacca, S.; Barbone, D.; Broaddus, V.C.; Gray, S.G.; O'Byrne, K.J.; Johnston, P.G.; Fennell, D.A.; Longley, D.B. Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. Eur. J. Cancer, 2012, 48, 1096-1107.
35. Marchion, D.C.; Bicaku, E.; Daud, A.I.; Sullivan, D.M.; Munster, P.N. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res., 2005, 65, 3815-3822.
36. Catalano, M.; Fortunati, N.; Pugliese, M.; Poli, R.; Bosco, O.; Mastrocola, R.; Aragno, M.; Boccuzzi, G. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol., 2006, 191, 465-472.
37. Wang, X. The expanding role of mitochondria in apoptosis. Genes Dev., 2001, 15, 2922-2933.
38. Lagneaux, L.; Gillet, N.; Stamatopoulos, B.; Delforge, A.; Dejeneffe, M.; Massy, M.; Meuleman, N.; Kentos, A.; Martiat, P.; Willems, L.; Bron, D. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells throughactivation of the death receptor pathway and potentiatesTRAIL response. Exp. Hematol., 2007, 35, 1527-1537.
39. Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Altucci, L.; Nervi, C.; Minucci, S.; Pelicci, P.G. Inhibitors of histone deacetylases induce tumor-selective apoptosisthrough activation of the death receptor pathway. Nat. Med., 2005, 11, 71-76.
40. Spiller, H.A.; Krenzelok, E.P.; Klein-Schwartz, W.; Winter, M.L.; Weber, J.A.; Sollee, D.R.; Bangh, S.A.; Griffith, J.R. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J. Toxicol. Clin. Toxicol., 2000, 38, 755-760.
41. Rasheed, W.K.; Johnstone, R.W.; Prince, H.M. Histone deacetylase inhibitors in cancer therapy. Expert Opin. Investig. Drugs, 2007, 16, 659-678.
42. Kelly, W.K.; Richon, V.M.; O'Connor, O.; Curley, T.; MacGregor-Curtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J.H.; Rifkind, R.; Marks, P.A.; Scher, H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res., 2003, 9, 3578-3588.
43. Buckley, M.T.; Yoon, J.; Yee, H.; Chiriboga, L.; Liebes, L.; Ara, G.; Qian, X.; Bajorin, D.F.; Sun, T.T.; Wu, X.R.; Osman, I. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J. Transl. Med., 2007,5, 49.
44. Qian, X.; Ara, G.; Mills, E.; LaRochelle, W.J.; Lichenstein, H.S.; Jeffers, M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int. J. Cancer, 2008,122, 1400-1410.
45. Plumb, J.A.; Finn, P.W.; Williams, R.J.; Bandara, M.J.; Romero, M.R.; Watkins, C.J.; La Thangue, N.B.; Brown, R. Pharma-codynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther., 2003, 2, 721-728.
46. Ramalingam, S.S.; Belani, C.P.; Ruel, C.; Frankel, P.; Gitlitz, B.; Koczywas, M.; Espinoza-Delgado, I.; Gandara, D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural msothelioma. J. Thorac. Oncol., 2009, 4, 97-101.
47. Steele, N.L.; Plumb, J.A., Vidal, L.; Tjørnelund, J.; Knoblauch, P.; Rasmussen, A.; Ooi, C.E.; Buhl-Jensen, P.; Brown, R.; Evans, T.R.; DeBono, J.S. A phase 1 pharmacokinetic and pharma-codynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res., 2008, 14, 804-810.
48. Kelly, R.J.; Sharon, E.; Hassan, R. Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 2011, 73, 256-263.
49. Chen, L.; Vogelzang, N.J.; Blumenschein, G.; Robert, F.; Pluda, J.M.; Frankel, S.R.; Sharma, S. Phase II trial of vorinostat (V) in combination with pemetrexed (PEM) and cisplatin (CDDP) in patients with advanced cancer. J. Clin. Oncol., 2007, 25, 18088.
50. Krug, L.M.; Curley, T.; Schwartz, L.; Richardson, S.; Marks, P.; Chiao, J.; Kelly, W.K. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydro-xamic acid. Clin. Lung Cancer, 2006, 7, 257-261.
51. Kelly, W.K.; O'Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J.P.; Schwartz, L.; Richardson, S.; Chu, E.; Olgac, S.; Marks, P.A.; Scher, H.; Richon, V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol., 2005, 23, 3923-3931.
52. Kindler, H.L. Systemic Treatments for Mesothelioma: Standard and Novel. Oncology, 2008, 9, 171-179.